real-time news and commentary for investors
Wednesday, Nov 9
2011, 1:47 PM
NPS Pharmaceuticals CEO (NPSP -2.9%) Francois Nader tells Minyanville that its drug aimed at...
NPS Pharmaceuticals CEO (NPSP -2.9%) Francois Nader tells Minyanville that its drug aimed at treating hypoparathyroidism will be successful following positive clinical testing of the treatment, helping offset problems with its experimental Gattex drug. Stifel Nicolaus expects both drugs to eventually win US approval, setting a price target of $11 on shares. Leerink Swann aims even higher with a $14-$16 price target - repping a tripling of the stock's current value.